RNA Interference Markets

Table of Contents

1. Overview

• 1.1 Objectives
• 1.2 Scope
• 1.3 Methodology
• 1.4 Executive Summary

2. RNA Interference (RNAi)

• 2.1 Introduction
• 2.2 Overview of RNA Interference
  • 2.2.1 Classes of Endogenous Small RNAs: siRNA, rasiRNA and miRNA
  • 2.2.2 Mechanism of RNAi In Vivo
• 2.3 Glossary
• 2.4 What Areas of Research Does RNAi Impact?
  • 2.4.1 RNAi Technology in Life Sciences Research, Drug Discovery and Development
    • 2.4.1.1 Clinical Trials Featuring RNAi-based Therapeutics
  • 2.4.2 RNAi Technology in Agriculture
    • 2.4.2.1 Companies Utilizing RNAi Technology for Agriculture

3. Technology Trends in RNAi Space

• 3.1 Overview
• 3.2 End-User Segmentation
• 3.3 Technologies for Inducing RNAi
  • 3.3.1 Methods for Detecting Gene Silencing
  • 3.3.2 Libraries of siRNAs/shRNAs to Knockdown Genes En Masse
    • 3.3.2.1 Publicly Available Large-scale Mammalian RNAi Libraries
    • 3.3.2.2 The RNAi Consortium (TRC)
    • 3.3.2.3 RNAi-related Consortia Based in Europe
  • 3.3.3 Comparison of Strategies for Target Validation
    • 3.3.3.1 Market Shifts in RNAi Space: Where Is It Headed?
    • 3.3.3.2 Intellectual Property and Patent Issues
    • 3.3.3.3 Funding in RNAi Space: Grants, Venture Capital and IPOs
    • 3.3.3.4 Partnerships, Alliances, Mergers and Acquisitions
  • 3.3.4 miRNA-Based RNAi: Leading Edge of RNAi Space
    • 3.3.4.1 Biological Function of miRNAs
    • 3.3.4.2 Role of miRNAs in Disease

4. RNAi Market Analysis

• 4.1 Overview
• 4.2 Market Data Collection and Respondent Pool
  • 4.2.1 Respondent Pool Characteristics
• 4.3 RNAi Technologies/Products in Research Applications
• 4.4 RNAi Technologies/Products: Market Shares (Quantitative)
• 4.5 Quantitative Metrics of RNAi Usage: Market Opportunity and Growth
  • 4.5.1 Growth of Various Segments in RNAi Space
  • 4.5.2 Product Formats and Representation in RNAi Marketplace
• 4.6 RNAi Marketplace: Challenges, Unmet Needs and Drivers
  • 4.6.1 Unmet Needs in RNAi Space
  • 4.6.2 RNAi Market: Qualitative Growth Drivers

5. The RNAi Landscape

• 5.1 Overview
• 5.2 Market Segmentation of RNAi and Segment Characteristics
• 5.3 Quantitative Market Opportunities in RNAi Space
  • 5.3.1 Opportunities in miRNA Space
  • 5.3.2 Opportunities in siRNA/shRNA Space
• 5.4 RNAi Product Offerings and Associated Business Models

6. Company Profiles

• 6.1 Alfacell Corporation
• 6.2 Allele Biotechnology and Pharmaceuticals, Inc.
• 6.3 Alnylam Pharmaceuticals
• 6.4 Ambion
• 6.5 Applied Biosystems Group
• 6.6 Asuragen, Inc.
• 6.7 Avalon Pharmaceuticals, Inc.
• 6.8 B-Bridge International, Inc.
• 6.9 Bio-Rad Laboratories
• 6.10 Calando Pharmaceuticals, Inc.
• 6.11 Cepheid
• 6.12 Cequent
• 6.13 Clontech Laboratories, Inc.
• 6.14 CombiMatrix Corporation
• 6.15 Cyntellect, Inc.
• 6.16 CytRx Corp.
• 6.17 Dharmacon
• 6.18 Dicerna
• 6.19 Galenea Corporation
• 6.20 GeneCopoeia, Inc.
• 6.21 GeneThera, Inc.
• 6.22 Genlantis
• 6.23 GenoSensor
• 6.24 GRL, Inc.
• 6.25 IDT
• 6.26 Imgenex Corporation
• 6.27 Ingenuity Systems
• 6.28 Isis Pharmaceuticals, LLC
• 6.29 Intradigm Corporation
• 6.30 Invitrogen
• 6.31 InvivoGen
• 6.32 LC Sciences
• 6.33 Lentigen Corporation
• 6.34 Merck & Co., Inc.
• 6.35 Mirus Bio Corporation
• 6.36 Monsanto
• 6.37 Nastech Pharmaceutical Company, Inc.
• 6.38 New England BioLabs
• 6.39 Nucleonics, Inc.
• 6.40 Open Biosystems, Inc.
• 6.41 OPKO Health, Inc.
• 6.42 OriGene
• 6.43 Panomics, Inc.
• 6.44 PhaseRx
• 6.45 Promega Corp.
• 6.46 Quark Pharmaceuticals, Inc.
• 6.47 RXi Pharmaceuticals Corporation
• 6.48 Senetek PLC
• 6.49 Sigma-Aldrich
• 6.50 Sirna Therapeutics
• 6.51 Sirnaomics, Inc.
• 6.52 SomaGenics, Inc.
• 6.53 System Biosciences
• 6.54 Tacere Therapeutics
• 6.55 Targeted Genetics Corporation
• 6.56 Third Wave Technologies
• 6.57 Traversa
• 6.58 Actigenics SA
• 6.59 Amaxa
• 6.60 AstraZeneca PLC
• 6.61 Cenix Bioscience GmbH
• 6.62 deVGen N.V.
• 6.63 DNAVision
• 6.64 Exiqon
• 6.65 Genovis
• 6.66 genOway
• 6.67 imaGenes GmbH
• 6.68 MWG Biotech AG
• 6.69 OZ Biosciences
• 6.70 Prosensa Holding
• 6.71 QIAGEN
• 6.72 RNAx GmbH (Germany)
• 6.73 Roche
• 6.74 Rosetta Genomics, Ltd.
• 6.75 Santaris Pharma A/S
• 6.76 Silence Therapeutics PLC
• 6.77 TaconicArtemis GmbH
• 6.78 TRANSAT
• 6.79 alphaGEN Co., Ltd.
• 6.80 Benitec, Ltd.
• 6.81 Bioneer
• 6.82 CytoPathfinder, Inc.
• 6.83 Genesis Research & Development Corp.
• 6.84 GeneDesign, Inc.
• 6.85 GNI Pharmaceutical Corporation
• 6.86 Koken Co., Ltd.
• 6.87 NanoCarrier Co., Ltd.
• 6.88 Oncolys Biopharma, Inc.
• 6.89 RealGene Bio-Technologies, Inc.
• 6.90 Samchully Pharmaceuticals
• 6.91 Samyang Corp.
• 6.92 Shanghai Biochip
• 6.93 Shanghai GenePharma Co.
• 6.94 Shanghai Genomics, Inc.
• 6.95 Transgene Biotek, Ltd.
• 6.96 Tekmira

INDEX OF TABLES

• Table 2.1: Advantages/Disadvantages of siRNAs and shRNAs as Inducers of RNAi in Mammalian Cells
• Table 2.2: Prevalence of siRNA-mediated RNAi in Disease Models, as Reported in Scientific Literature
• Table 2.3: RNAi-based Therapeutics in Clinical Trials
• Table 2.4: Suppliers of Enabling Technologies and Tools in RNAi Space
• Table 2.5: Suppliers of siRNA/shRNA Products (by Product/Service Class)
• Table 3.1: Currently Utilized Technologies for Inducing RNAi-Mediated Knockdown
• Table 3.2: Comparison of mRNA Detection Technologies
• Table 3.3: Characteristics of Various Publicly available Mouse and Human RNAi Libraries
• Table 3.4: Comparison of Formats for Library-Based Gene Knockdown
• Table 3.5: Strategies for Target Validation by Pharma/Biotech: RNAi and Others
• Table 3.6: Seminal Patents in RNAi
• Table 3.7: Venture Capital Raised by Selected Companies in the RNAi Space
• Table 3.8: List of Public Biotech Companies in RNAi Space
• Table 3.9: Disease-Related miRNAs
• Table 3.10: Publicly Available Computational Programs for Identifying miRNA Sequences/Targets
• Table 3.11: SWOT Analysis of siRNA Oligonucleotides
• Table 3.12: Transfection Reagents (Lipid-Mediated Delivery)
• Table 3.13: shRNA Plasmid Constructs
• Table 3.14: shRNA Pooled Libraries or Arrayed Collections (Retroviral/Lentiviral Delivery)
• Table 5.1: RNAi Market Segmentation and Research Settings
• Table 5.2: Segment 1: Basic Life Science Research Utilizing RNAi Tools and Technologies
• Table 5.3: Segment 2: RNAi for Drug Discovery and Development
• Table 5.4: Segment 3: RNAi Research for Development of RNAi Therapeutics
• Table 5.5: Segment 4: RNAi Fee-for-Service Business
• Table 5.6: Grants Awarded and Research Spending in miRNA Space, 2005-2008
• Table 5.7: RNAi Opportunity and Market Size: Quantitative Model, 2006-2009

INDEX OF FIGURES

• Figure 2.1: The miRNA Processing Pathway
• Figure 2.2: Growth of Scientific Publications Addressing miRNAs, 2001-2008
• Figure 2.3: Mechanisms of Small RNA-induced Gene Regulation
• Figure 2.4: Types of RNAi Compounds
• Figure 2.5: Breakdown of Scientific Publications Related to RNAi by Geographic Region, 2007-2008
• Figure 3.1: End-User Segmentation of RNAi Space
• Figure 3.2: RNAi Patents Filed Globally, by Geographical Origin
• Figure 3.3: Selected Deals in RNAi Space
• Figure 4.1: Geographical Breakdown of RNAi End-User Survey Respondents
• Figure 4.2: Affiliation of RNAi End-User Survey Respondents
• Figure 4.3: Utilization of RNAi Technologies/Products by Respondent Pool
• Figure 4.4: RNAi Utilization Period: Breakdown of Respondent Pool
• Figure 4.5: Research Applications Using RNAi Technologies/Products
• Figure 4.6: Types of RNAi Technologies Currently Utilized
• Figure 4.7: RNAi Technologies Most Commonly Utilized Currently by End-Users
• Figure 4.8: Types of RNAi Technologies: Expected Use in Six to 18 Months
• Figure 4.9: Evolution of Market Shares of RNAi-Inducing Technologies
• Figure 4.10: Number of Experiments Involving RNAi Conducted per Week
• Figure 4.11: Range of Research Dollars Spent Monthly on RNAi Research
• Figure 4.12: RNAi Experiment Throughput Correlated with Type of RNAi Technology Used
• Figure 4.13: Current RNAi Market Share by Segments
• Figure 4.14: Growth/Decline Rate of RNAi Marketplace Segments (Six to 18 Months)
• Figure 4.15: Product Formats Utilization for RNAi Research (Current and Six to 18 Months)
• Figure 4.16: Companies Offering Product Formats for Currently Used RNAi Products
• Figure 4.17: RNAi Product Offerings/Formats Use (Projections-Six to 18 Months)
• Figure 4.18: Percentage Change of RNAi Product Offerings/Formats (Six to 18 Months)
• Figure 4.19: Key Challenges Faced by End-Users in RNAi Space
• Figure 4.20: Unmet Needs in RNAi Space Ranked by Importance to End-Users
• Figure 5.1: Growth and Evolution of miRNA Space
• Figure 5.2: Elements of RNAi Value Chain
• Figure 5.3: Growth and Evolution of RNAi (siRNA/shRNA) Space
• Figure 5.4: Market Revenues Based on Components of siRNA Experimental Paradigm